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1. Introduction 
Hysterectomy (from Greek ὑǔǕέρα hystera "womb" and εκǕομία ektomia "a cutting out of") is 
the surgical removal of the uterus. Hysterectomy may be total (removing the body, fundus, 
and cervix of the uterus; often called "complete") or partial (removal of the uterine body 
while leaving the cervix intact; also called "supracervical"). It is the most commonly 
performed gynaecological surgical procedure although the incidence of hysterectomy varies 
widely across the world.1 This is the case even when one considers only developed countries 
with comparable resources. In 2003, over 600,000 hysterectomies were performed in the 
United States alone, of which over 90% were performed for benign conditions.2 In the USA a 
woman’s life-time risk of hysterectomy is 25%, which compares to a much lower risk of 
10.4% in Denmark.3 In England and Wales the hysterectomy rate in NHS hospitals is 
estimated at 28 per 10,000 women per annum.4 Even within each country, there are large 
regional variations.5 Such rates being highest in the industrialized world has led to the 
major controversy that hysterectomies are being largely performed for unwarranted and 
unnecessary reasons.  
Oophorectomy is frequently done together with hysterectomy to decrease the risk of ovarian 
cancer. However, recent studies have shown that prophylactic oophorectomy without an 
urgent medical indication has serious consequences.6 Apart from the current occurrence of 
estrogen deficiency symptoms, women who are oophorectomized, particularly at an early 
age experience an increased risk of ischaemic heart disease as well as death from 
cardiovascular disease. Oophorectomy also leads to early loss of bone and an increased risk 
of osteoporotic fracture and may also be linked to impaired cognitive function. The impact 
on psychological health could also be substantial leading to long lasting anxiety, depression, 
loss of self-esteem and well-being and may also indirectly or directly give rise to problems 
of sexual function. This effect is not limited to pre-menopausal women; even women who 
have already entered menopause were shown to have experienced a decrease in long-term 
survivability post-oophorectomy.7 
Hysterectomy and bilateral oophorectomy has surgical risks as well as long-term effects. So 
the surgery should normally be recommended only when other treatment options are not 
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available. However, it is expected that the frequency of hysterectomies for non-malignant 
indications will fall as there are good alternatives in many cases.8 As most of the 
hysterectomies are conducted for benign conditions, including fibroid disease, dysfunctional 
uterine bleeding, endometriosis, benign adnexal mass, pelvic relaxation/prolapse and 
chronic pelvic pain, many of these conditions can be effectively treated with alternative 
treatment modalities of which the LNG-IUS is probably the easiest, safest, most effective 
and most economical of the conservative alternatives of hysterectomy. In this chapter, a 
short review is given about these alternative treatments with special focus on current and 
future LNG-releasing systems. 
2. Morbidity and mortality of hysterectomy 
A multicenter study conducted in 102 hospitals in Canada evaluated the morbidity and 
mortality rates of laparoscopic, abdominal, and vaginal hysterectomy.9 One thousand seven 
hundred ninety-two women underwent hysterectomy for benign, nonobstetric indications. 
The overall hysterectomy-related morbidity rate was 6.1%. The rate of morbidity was higher 
in the laparoscopic supracervical hysterectomy (LASH) group (9.4%) than in the abdominal 
hysterectomy (AH) group (5.2%, p<0.01), but no significant difference was noted between 
AH and vaginal hysterectomy (VH) (8.6%). The incidence of intraoperative bowel injury 
was 0.4% in the LASH group (a trocar injury in a patient) and 0.3% in the AH group. 
Bladder injury was encountered in two patients in the LASH group (0.9%) and in another 
two in the AH group (0.1%). Ureteral injury occurred in a patient in the AH group (0.07%). 
There were no cases of intraoperative vascular injury. Vaginal hysterectomy was associated 
with more urinary retention and hematoma formation than the other two groups. 
Discordant diagnosis was noted in four cases (two missed endometrial cancer, atonic and 
distended bladder mistaken for an ovarian cyst, and pelvic tuberculosis). The conversion 
rate to laparotomy was 1.7% in the LASH group and 0.4% in the VH group, and the 
incidence of reoperation was 0.4% in the AH group. It was concluded that besides the 
overall hysterectomy-related morbidity rate of 6.1%, compared with other types of 
hysterectomy, more urinary retention and hematoma formation occur after VH. LASH is 
associated with a higher morbidity rate than AH; mainly because of conversion to 
laparotomy and blood transfusion. 
A review by Banu et al10 on the health outcomes following hysterectomy reports that 
hysterectomy is highly effective, resulting in high satisfaction rates11,12, improvements in 
health-related quality-of-life measures13,14 and sexual functioning15,and of course a complete 
resolution of the menstrual disturbance without the possibility of recurrence. However, 
hysterectomy is a major operation which causes discomfort and considerable disability in 
the weeks following surgery16, has mortality rates in the range 0.38–1 per 100017,18, severe 
complications in 3% of women9, and minor morbidity (mainly fever and infection) in up to 
30% women. 
Hysterectomy is also thought to be associated with urinary incontinence many years after 
the operation19, and may cause early ovarian failure (and the consequences thereof).20 
These issues, including the high surgery and hospital cost implications21, have resulted in 
the search for effective alternatives. 
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3. Alternatives to hysterectomy in women with bleeding disorders and other 
gynaecological conditions 
A Non-steroidal anti-inflammatory drugs 
Mefenamic acid, and the antifibrinolytic agent tranexamic acid are effective treatments and 
are considered first-line treatment for menorrhagia.22 The efficacy of these treatments has 
been demonstrated in several randomized trials and reported in systematic reviews.23,24 
Tranexamic acid reduces menstrual loss by about 50% and mefenamic acid by a third. Both 
drugs also relieve menstrual cramps. 
B Systemically administered hormones 
Cyclical progestogens given during the luteal phase of the cycle are ineffective, but are 
effective when given continuously for 21 days.25 Side effects such as breakthrough bleeding, 
breast tenderness, weight gain, alteration in libido and depression reduce compliance. The 
additional contraceptive effect limits their use in women who wish to conceive. Where 
contraception is desired, the combined oral contraceptive pill appears to be a better choice 
for the treatment of menorrhagia. The hormones work by inhibiting the growth and 
development of the endometrium, thus significantly reducing blood loss. 
C Locally administered hormones 
The main focus of this section will be on the local administration of levonorgestrel (LNG) 
using an intrauterine drug delivery system (IUS) as LNG is a potent progestogen with many 
advantages.26 The progesterone-releasing intrauterine device (IUD) will not be discussed as 
the Progestasert® IUD is not commercialized anymore. The natural hormone is much weaker 
than LNG and, therefore, less suitable for the treatment purposes described in this paper. 
Our research group has been involved in the clinical development of frameless and framed 
LNG-releasing intrauterine systems since 1997. Another chapter in this book focuses on the 
effect of these systems on menstrual blood loss in women with and without heavy 
menstrual bleeding or menorrhagia. This section will mainly focus on the differences 
between these novel devices compared to the Mirena® LNG-IUS (BayerSchering AG, Berlin, 
Germany). In addition, the use of the LNG-IUS will be discussed for the treatment of 
precancerous lesions of the endometrium, including early endometrial cancer of the 
endometrium, conditions that usually are treated by hysterectomy. 
In order to be successful as a method for intrauterine treatment, the prerequisite is that the 
following conditions are met. The method should: 
1. be easy and safe to apply 
2. be well-tolerated and fit in cavities of every size and shape 
3. be well retained 
4. release a sufficient amount of active substance per day 
5. preferably release a high dosage during the first few weeks to establish fast and 
profound suppression of the endometrium 
6. be long-acting 
7. have few side effects and 
8. be easy to remove  
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a. Comparison between Femilis® LNG-IUS and Mirena® LNG-IUS  
Figure 1 depicts both intrauterine systems. The design of Femilis® is slimmer with shorter 
crossarms and thinner stem than Mirena®. Both release a similar amount of LNG (20 
µg/day) except for the first weeks whereby comparative in vitro release studies showed that 
the release rate of Femilis® is approximately 2 to 3 times higher. Femilis® and Mirena® have a 
duration of action of at least 5 years. 
 
Fig. 1. Femilis® LNG-IUS.  
 
Fig. 2. Mirena® LNG-IUS 
The difference in design is important as it has a bearing on the easiness and safety of the 
insertion procedure as well as on the acceptability and retention of the LNG-IUS. 
As Femilis® is significantly smaller that Mirena®, it is suitable for parous as well as 
nulliparous women. Women with narrow, but not too narrow, uterine cavities tolerate the 
LNG-IUS. Figure 3 shows the blister package of Femilis® with uterine sound. 
28 mm
 32 mm 
2.4 mm 
3.8 mm 
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Fig. 3. Blister package with Femilis® inserter and uterine sound. 
Figure 4 illustrates the insertion procedure of the Femilis® IUS and Figure 5 the insertion 
procedure of the Mirena® LNG-IUS. 
 
Fig. 4. Insertion of Femilis®. The applicator is positioned against the cervix (left) and pushed 
into the uterine cavity (middle) until its front end reaches the fundus (right). The inserter 
tube is then removed and the thread is trimmed at 2 cm from the cervix. Note: During 
insertion the sidearms unfold protecting against perforation. 
Uterine cavities differ considerably in size and shape, and the uterus is subject to changes in 
size and volume during the menstrual cycle.27,28 These changes are most pronounced at the 
time of menses. These individual variations in size and shape of the human uterus are 
probably greater than variations of the human foot (H.M. Hasson). Research has shown that 
if the width of the uterine cavity is too small, side effects and complications are likely to 
occur. The crossarms of standard T-shaped IUDs are frequently too long for a large number 
of uterine cavities, as the average transverse diameter of the uterine cavity in the majority of 
women is smaller than the span of the crossarms of the IUD. The average transverse 
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Fig. 5. Insertion of Mirena®: 1) The package is opened and the shaft of the insertion 
instrument is grasped as shown. The arms of the IUS should be in horizontal position 
1 2 
4 5 
7 8 
3 
6 
9 
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(adjustment can be done on the sterile inner surface of the peel pack). 2) The threads are 
now pulled until both knobs close the open end of the front end of the inserter. 3) The 
thread is then fixed in the cleft at the end of the inserter. 4) The sidearms of the IUS should 
be in the correct position as they should fold out horizontally. If not, open the arms by 
pulling the slider back to the raised mark on the shaft. Align the open arms on the sterile 
surface of the package and return the slider to its previous position. Check that the threads 
are still tight and that the arms have moved back into the inserter. 5) Set the flange at a 
distance from the knobs corresponding to the uterine sound measure by using the scale 
marked on the insertion tube. Note that this measurement is from the end of the inserter to 
the top edge of the flange. 6) Mirena® is now ready to be inserted. Hold the slider with the 
forefinger or thumb firmly in the most distal position. Move the inserter carefully through 
the cervical canal into the uterus until the flange is situated at a distance of about 1.5 – 2 cm 
from the cervix to give sufficient space for the arms to open. Do not force the inserter. 7) 
While holding the inserter steady, release the arms of the IUS by pulling the slider back until 
it reaches the raised mark on the shaft. 8) Holding the slider firmly, push the inserter gently 
inward until the flange touches the cervix. The IUS should now be at the fundus. 9) Holding 
the inserter firmly in position, release the IUS by pulling the slider all the way back. Remove 
the inserter and cut the strings at 2 cm from the cervix. 
diameter of the uterine cavity at the fundal level in nulliparous women between 15 and 34 
years of age, as well as in many parous women, is much smaller than the length of the 
crossarms of most currently used T-shaped IUDs resulting in dimensional problems. The 
length of the crossarms of the Mirena® LNG-IUS is 32 mm. The average fundal transverse 
dimension in nulliparous as well as parous women is only around 25 to 27 mm. Recent 3-D 
sonography studies compared women with abnormally and those with normally located 
IUDs with respect to their indication for sonography and found that the proportion of 
patients whose principal indication for sonography was bleeding, pain or bleeding and pain 
were significantly greater in those with an abnormally located IUD, including imbedded 
IUDs, compared with those whose IUD was not located abnormally on 3-D sonography.29,30 
It should be noted that standard 2-D sonography is not able to detect many abnormally 
located IUDs particularly with regard to abnormal location of the sidearms of the IUD. 
Accurate location of the sidearms is only possible by hysteroscopy and with 3-D coronal 
sonography, as shown in Figure 6. Due to the shorter crossarms of the Femilis® LNG-IUS it 
has been demonstrated in clinical trials that the IUS fits better in uterine cavities with small 
transverse dimensions. This indicates that side effects (e.g., pain, bleeding and expulsion) 
due to incompatibility can be avoided by reducing the length of the crossarms. IUDs that do 
not fit well contribute to early discontinuation.31 In addition, insertion of the Femilis® IUS is 
straightforward. Following uterine sounding, the IUS is simply pushed in the uterine cavity, 
up to the fundal wall. The ease and safety of this insertion technique was demonstrated in a 
multicenter clinical trial.32,33  
b. Use of the LNG-IUS in women with precancerous or early cancer of the endometrium  
The use of the LNG-IUS as an alternative to hysterectomy for treatment of heavy menstrual 
bleeding was covered in another chapter in this book. Other uterine pathologies such as 
precancerous changes of the endometrium and even early endometrial cancer of the uterus 
can effectively be treated by the LNG-IUS. Our group evaluated the effect on endometrial 
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Fig. 6. Left: Femilis® fitting snugly in a small uterine cavity. Right: Mirena® showing 
unfolded and embedded crossarm due to incompatibility with the narrow uterine cavity. 
non-atypical and atypical hyperplasia in 20 women. The aim of the study was to evaluate 
the long-term cure (remission) rate. All women in this small series developed a normal 
endometrium, except one asymptomatic woman with atypical hyperplasia who still had 
focal residual non-atypical hyperplasia at 3 years follow-up in the presence of a thin (<4 
mm) endometrium. This patient is being followed-up on a regular basis. It was concluded 
that continuous intrauterine delivery of LNG appears to be a promising alternative to 
hysterectomy for the treatment of endometrial hyperplasia and could enhance the success 
rate when compared with other routes of progestogen administration as well as intrauterine 
progesterone delivery.34 As many women with atypical hyperplasia harbour cancer cell, 
patients should be followed-up long-term and the endometrium should continuously kept 
suppressed with a  LNG-IUS. 
Two cases of early, respectively well- and moderately differentiated endometrial carcinoma 
were also effectively treated with the LNG-IUS. Below is the summarized report of one of 
these patients. The patient presented with minimal postmenopausal bleeding. An outpatient 
endometrial pipelle biopsy was performed which revealed a moderately differentiated 
adenocarcinoma (Figure 7) with minimal myometrial invasion (Clinical FIGO stage I).35 An 
LNG-IUS (Femilis®) was inserted and advice was given to conduct a repeat biopsy within 
the next 3 to 6 months. Spotting continued for several weeks and then stopped. As the 
patient was completely free of symptoms 6 months after insertion of the LNG-IUS, a pelvic 
transvaginal ultrasound was performed, including a 3-D ultrasound. The uterus appeared 
completely normal, and there was no evidence of any pathology. The endometrium showed 
normal thickness, and there was no evidence of any endometrial abnormality or myometrial 
invasion. The LNG-IUS was identified in situ, as expected. Six months later, in order to 
ascertain complete remission, it was decided to remove the LNG-IUS and to perform a full 
D&C. The uterine sound length was 6 cm. The whole cavity was explored, and very scant 
tissue was removed. Histological examination of the specimen revealed a secretory  
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Fig. 7. Left: Endometrial curetting prior to therapy, irregular cribriform glands, and mild 
atypia: moderately-differentiated endometrioid carcinoma (H&E 100x). Right: Endometrial 
curetting post-therapy, small regular glands with tubal metaplasia, surrounded by 
decidualised stroma (H&E 100x). 
endometrium without signs of hyperplasia or atypia (Figure 7). A new LNG-IUS was 
inserted as a precaution. The patient was again examined two years following initial 
treatment. She had no symptoms, and vaginal ultrasound showed a very thin endometrium 
and normal position of the LNG-IUS in the uterine cavity.  
c. Use of the LNG-IUS in women with primary or secondary dysmenorrhea, 
endometriosis/adenomyosis and chronic pelvic pain 
Our group evaluated the effect of a frameless LNG-IUS releasing 14 µg of LNG/d (Figure 8) 
on menstrual pain in women with primary and secondary dysmenorrhea.  
 
Fig. 8. The frameless FibroPlant® LNG-IUS 
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Eighteen insertions were performed in women between 16 and 52 years of age. Eight women 
were categorized as having primary and 10 having secondary dysmenorrhea. Twelve women 
complained of heavy bleeding. Two women had significant fibroids and three were suspected 
to have adenomyosis. All women, except one with significant fibroids, reported much reduced 
pain, no pain at all, or strongly reduced bleeding, which started as soon as one month after 
insertion of the frameless LNG-IUS. The results of this small study suggest that the LNG-IUS 
could be an effective method in women with primary or secondary dysmenorrhea, associated 
or not with excessive menstrual bleeding, and avoid surgery in many of them as both bleeding 
and pain are effectively treated with the LNG-IUS. An additional advantage is that the LNG-
IUS is a potent contraceptive as well. The absence of a frame is particularly advantageous in 
these cases as it does not elicit uterine contractions. 
Endometriosis affects almost 10–20% of women of reproductive age, while 70–90% of 
women with chronic pelvic pain (CPP), dysmenorrhea, dyspareunia, infertility and 
menstrual disturbances also have endometriosis, a disease that impairs patients’ quality of 
life.36 Many therapies are proposed. These include nonsteroidal anti-inflammatory drugs, 
antiestrogens, progestogens such as depot medroxyprogesterone acetate (DMPA), GnRH 
analogues to induce pseudo-menopause, androgen derivatives (danazol) and continuous 
combined oral contraceptives (COC) to induce pseudo-pregnancy. Medical treatments are 
based on the reduction of lesions or on ovarian estrogen suppression; however, adherence 
and long-term therapy continue to represent a challenge in the management of 
endometriosis. Because of the profound hypoestrogenism provoked by some of these drugs, 
bone mineral density is the principal concern that limits their use to 6 months, although 
longer treatment with add-back hormone therapy is possible. GnRH-a is also expensive and 
not readily available to women worldwide, especially in developing countries. 
One of the options to treat these conditions, and alleviate the pain complaints, is the 
levonorgestrel-releasing intrauterine system. Bahamondes et al. recently reviewed the 
literature regarding the use of LNG-IUS (Mirena®) in women with endometriosis, 
adenomyosis, cyclic pelvic pain and dysmenorrhea.37 They found that all studies reported 
an improvement in pelvic pain and dysmenorrhea, and a reduction in menstrual bleeding. 
One study found an improvement in the staging of the disease at 6 months of use, and the 
studies that evaluated the use of LNG-IUS in women with adenomyosis reported a 
reduction in uterine volume. Furthermore, the only study in which women were followed 
up for 3 years after insertion found improvement in pelvic pain at 12 months of use, but no 
improvement after that period. They concluded that the use of LNG-IUS is an alternative for 
the medical treatment of women suffering from endometriosis, adenomyosis, chronic pelvic 
pain or dysmenorrhea, but that experience is limited and long-term studies are necessary to 
reach definitive conclusions. Other authors came to the same conclusion.38 However, for 
women who do not wish to become pregnant, this device offers the possibility of at least 5 
years of treatment following one single intervention. It is to be expected that many of these 
women, without further fertility, could avoid surgical treatment which would be viewed as 
an enormous benefit for those concerned.  
Given the above scientific evidence, it should be concluded that the LNG-IUS is effective for 
the treatment of the most frequently occurring gynaecological conditions for which 
gynaecologists are consulted. The use of local medical treatment has many advantages and 
should, therefore, be considered as the first line treatment before a surgical intervention.39,40 
In a randomized trial comparing the LNG-IUS with hysterectomy, 42% in the LNG-IUS 
group subsequently underwent hysterectomy, and, thus, surgery and the associated risks 
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with surgery were avoided in 58% of the women. The number of hysterectomies for 
menorrhagia in England has fallen substantially to just over one third (36%) of the number 
of a decade ago (Figure 9).41 This trend can be explained by an increase in medical treatment 
as well as by the more widespread use of endometrial resection or ablation.  
 
Fig. 9. Number of hysterectomies for menorrhagia from 1989-90 to 2002-3 in NHS trusts in 
England 
Active education of good management of menorrhagia and promotion of effective medical 
management in primary care halves the number of referrals to secondary care. However, 
despite the strong evidence that medical treatments, in particular the LNG-IUS, are effective, 
many hysterectomies and endometrial ablations/resections are still performed annually 
without first evaluating medical treatment.37 
d. Health-related quality of life and cost of the LNG-IUS vs. hysterectomy  
Hurskainen et al. (Finland) compared outcomes, quality-of-life issues, and costs of the LNG-
IUS vs. hysterectomy in the treatment of menorrhagia.42 After 5 years of follow-up, 232 
women (99%) were analyzed for the primary outcomes. The 2 groups did not differ 
substantially in terms of health-related quality of life (HRQL) or psychosocial well-being. 
Although 50 (42%) of the women assigned to the LNG-IUS group eventually underwent 
hysterectomy, the discounted direct and indirect costs in the LNG-IUS group ($2817 [95% 
confidence interval, $2222-$3530] per participant) remained substantially lower than in the 
hysterectomy group ($4660 [95% confidence interval, $4014-$5180]). Satisfaction with 
treatment was similar in both groups. Compared to other medications the LNG-IUS is much 
cheaper per menstrual cycle unless it is removed before 5 years. Long-term acceptability is 
therefore essential.43  
D Endometrial ablative techniques 
In recent years various surgical techniques have been developed to ablate the endometrium. 
An excellent review on these techniques was recently published.10 The reader is therefore 
referred to this paper. It suffices to make some observations and conclusions. 
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The endometrial ablative techniques can be divided into two broad groups: the first-
generation hysteroscopic endometrial ablation (HEA) procedures performed under direct 
vision, and the second-generation non-hysteroscopic endometrial ablation (NHEA) 
procedures which are largely ‘blind’. These techniques are mainly used to treat women with 
excessive menstrual bleeding. They are summarized in Table 1. 
TECHNIQUE ADVANTAGES  DISADVANTAGES 
Hysteroscopic endometrial 
ablation  
(first generation) 
  
Transcervical resection of the 
endometrium (TCRE) utilizes 
an electrosurgical cutting loop 
 
Transcervical rollerball uses 
an electrosurgical rollerball to 
coagulate the tissues 
 
Laser photo-vaporization uses 
a high-energy beam to destroy 
endometrial tissues 
TCRE results in satisfactory 
reduction of menstrual loss in 
up to 90% of cases  
 
The technique is significantly 
safer than hysterectomy  
 
Rollerball endometrial 
ablation is the easiest 
technique to master and 
generally the quickest to 
perform. The risk of 
perforation is greatly 
diminished 
These first-generation techniques 
require a general or regional 
anaesthetic, specialized surgical 
skill and often carry a small risk 
of perforation at the thin cornua, 
haemorrhage, fluid overload and 
infection  
 
Recurrence of menorrhagia or 
dysmenorrhoea and pelvic pain 
are principal reasons for further 
surgery  
 
The cost of the laser-photo-
vaporization machine as well as 
the single-use laser fibre limits its 
more general application 
Non-hysteroscopic 
endometrial ablation (NHEA) 
(second generation) 
  
Cavatherm device 
 
Hydrothermablation 
ThermaChoice  
 
MenoTreat System 
 
VestaBlate 
 
HydroThermAblator 
 
NovaSure 
 
GyneLase 
 
MEA 
These second-generation ‘less 
invasive’ techniques are 
designed to ablate the full 
thickness of the endometrium 
by the controlled application 
of heat, cold, microwave or 
other forms of energy 
 
The techniques are simpler 
and quicker to perform than 
hysteroscopic methods, while 
satisfaction rates and 
reduction in menstrual blood 
loss are high (up to 90%) 
Women choosing one of these 
options need to be aware that 
they are likely to continue to 
experience some degree of 
menstrual bleeding and that 
further surgery may be necessary 
for persistent heavy bleeding  
 
The data on the safety of all the 
second generation techniques are 
as yet incomplete, but all systems 
appear to be associated with 
minimal complication rates 
Table 1. Endometrial ablative techniques. 
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Myomectomy (laparoscopic, robotic assisted laparoscopic, vaginal, laparoscopic 
assisted vaginal, laparotomy) 
Advantages Disadvantages 
-Overall results are 81% resolution of 
menorrhagia symptoms, with similar 
results for pelvic pressure symptoms 
-Laparoscopic approach to 
myomectomy is associated with a 
shorter postoperative recovery period, 
shorter hospital stay and cost-saving 
benefits 
-Robotic-assisted laparoscopic 
myomectomy could considerably 
reduce learning curve (Nisolle et al. 
2011) 
-Vaginal myomectomy is only 
possible in selected cases 
-Combined approach renders 
haemostasis and uterine repair easier 
than by the laparoscopic approach alone 
 
-Only a limited range of fibroids is amenable to 
the laparoscopic approach 
-Risk of conversion to open myomectomy is 2-8% 
-Rupture of the pregnant uterus has been 
reported after laparosopic myomectomy 
-Myomectomy performed via a laparotomy is 
associated with increased blood loss, operating 
time, pain, postoperative morbidity and longer 
hospital stay than hysterectomy, while an 
additional procedure (such as repeat 
myomectomy or hysterectomy) is necessary in 
20–25% of women 
-Recurrence of fibroids following myomectomy 
occurs in up to 50% 
-Myomectomy carries a risk of postoperative 
pelvic adhesions 
GnRH analogues in the management of uterine fibroids 
Advantages Disadvantages 
-GnRH analogues prior to either 
hysterectomy or myomectomy has 
shown that uterine volume and size, 
as well as fibroid volume, were all 
reduced, as were pelvic symptoms 
-Hysterectomy is rendered easier, 
with reduced operating time, and a 
greater proportion of hysterectomy 
patients were able to have a vaginal 
rather than an abdominal procedure  
-Blood loss and rate of vertical incision 
were reduced for both myomectomy 
and hysterectomy 
-Duration of hospital stay was 
reduced 
-Disadvantages of GnRH analogues include cost, 
menopausal symptoms (but can be prevented by 
‘add-back’ HRT) and, with prolonged therapy, 
bone demineralization 
-Some believe that benefits do not justify the 
costs 
-GnRH analogues render surgical planes less 
distinct, perhaps due to softening of the fibroids, 
which makes enucleation more difficult 
-Their use as primary therapy in younger women 
is questionable as fibroids re-grow to their 
original size within a few months of 
discontinuation of treatment 
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Uterine artery embolization (UAE)  
Advantages Disadvantages 
-Clinical success rates are good with 
good fibroid shrinkage rates (10–70%) 
and symptom improvement (70–94%) 
-UAE is now widely practiced in 
Western Europe and North America, 
and the National Institute for Clinical 
Excellence (NICE) in the UK has 
decreed that it can be routinely offered 
as a primary treatment for uterine 
fibroids, although it is recommended 
that all procedures are registered 
-However, the fact remains that UAE 
has never been compared with 
conventional treatments in a 
prospective randomized controlled 
trial (RCT), as either a pilot or a full 
study 
-There is also a lack of long-term data  
-Complications secondary to arterial puncture, 
contrast injection, arterial catheterization and 
non-target-organ embolization are intrinsic to all 
embolization procedures, but are uncommon, 
and further minimized by operator experience 
and good technique 
-Chronic discharge is a frequent complication, 
affecting up to 7% of patients 
-Infections are also more common with larger 
fibroids 
-Fibroid extrusion occurs in about 10% of cases. 
Larger ones may necessitate a surgical procedure 
for removal, especially if impacted at the cervix 
-Clinical features of the so-called post-
embolization syndrome include a flu-like illness, 
high temperature, high white cell count and a 
feeling of malaise, and may be due to release of 
cytokines and toxins from the ischaemic tissue. 
This might be difficult to differentiate from sepsis 
Table 2. Summarizes these new approaches, their advantages and disadvantages (adapted 
from Banu et al.10).  
A Cochrane review concluded that while short-term follow-up studies might indicate an 
advantage for endometrial ablation, longer-term studies show a narrowing of the gap, and 
hysterectomy appears to have consistently higher rates of satisfaction and better health-
related quality-of-life outcomes.44 A study conducted by Maia et al. is also worth 
mentioning in this respect.45 They investigated 106 women with HMB. After endometrial 
resection, the women were randomized into two groups, 53 women in each. Women in the 
treatment group were fitted with Mirena®. In this group, amenorrhoea was achieved in 72% 
of cases after 3 months, in 89% after 6 months and in 100% after 1 year. In the resection-only 
group, the corresponding numbers were 19%, 17% and 9%, and in this group, 19% of the 
women underwent a second resection. 
A second study by Maia et al. (CEPARH, Brazil) was recently reported at the World 
Congress on the Menopause (Abstract Book p. 74). Ninety-two perimenopausal women with 
menorrhagia, dysmenorrhea and premenstrual syndrome (PMS) were enrolled in this study. 
Sixty-two patients had adenomyosis and the remaining 30 had submucous and intramural 
myomas. The use of the LNG-IUS (Mirena®) following endometrial resection significantly 
increased amenorrhoea rates. The rate was 98% in the fifth year. Complete resolution of 
dysmenorrhea and PMS was reported by over 90% of patients. In historical controls 
submitted to endometrial resection, the amenorrhoea rate was only 20% with a failure rate 
of 40%. This study also showed an inhibition of the expression of aromatase in the ectopic 
glands in the myometrium of patients with adenomyosis, thereby contributing towards 
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interrupting the progression of the disease. This may explain why the rates of amenorrhoea 
are far superior to those achieved with endometrial resection alone. It was concluded that 
endometrial resection with LNG-IUS is a viable alternative to hysterectomy in 
perimenopausal women. 
E. Alternative therapies for the management of fibromyomas  
Uterine myoma (leiomyoma, fibromyoma, fibroid) is a very common disease. They are more 
common in certain ethnic populations, especially the Afro-Caribbean.46 Leiomyomas occur 
with an incidence of up to 77%.47 Fibroids can cause menorrhagia, pelvic pain/discomfort, and 
bladder and bowel compression symptoms. They are often asymptomatic but some 25-50% of 
women will experience symptoms such as menorrhagia and pelvic discomfort. About 5% of 
the fibroids are intracavitary and submucosal and are most difficult to treat.48,49 Hysterectomy 
is still the most commonly used procedure although medical treatments are preferable.50,51 
Uterine fibroids are responsible for 30% of hysterectomies. Notwithstanding the success of 
radical surgery, it is not always desirable particularly in the younger woman desiring fertility. 
Also psychological factors play a role as the uterus has been regarded as a sexual organ, a 
source of energy and vitality, and a maintainer of youth and attractiveness. Many women, 
therefore, might wish to avoid a hysterectomy, even when their families are complete.  
Recently, new conservative treatment options have been developed such as the treatment 
with GnRH analogs and the levonorgestrel-releasing intrauterine system (LNG-IUS).52,53 
GnRH analogs, however, are only temporarily indicated before surgical intervention. 
4. Conclusion 
Because of its multiple health benefits, the LNG-IUS is likely to continue to conquer the 
worldwide markets to treat frequent gynaecological conditions and simultaneously provide 
contraception when needed. In addition, The LNG-IUS may also offer major benefits for the 
prevention of uterine pathologies and conditions, including endometrial polyps, endometrial 
hyperplasia, endometrial carcinoma in association or not with tamoxifen treatment of breast 
cancer, peri-menopausal menstrual disturbances, post-menopausal endometrial hyperplasia 
with hormone replacement therapy, endometrial hyperplasia and uterine myomas, 
endometriosis, adenomyosis, acute pelvic inflammatory disease and infertility.27 Just as we are 
very conscious about the health benefits of estrogens in the prevention of osteoporotic 
fractures, the LNG-IUS and other hormone-releasing systems will be used mostly for the 
prevention of benign diseases in gynaecology. However, successful treatment of precancerous 
lesions and early cancer of the endometrium are within reach of the LNG-IUS. 
The challenge also remains to promote novel LNG-IUSs who are easy to apply and are 
designed to fit in uterine cavities with different size and shape to improve tolerance and 
maximize continued use. Furthermore, new conservative approaches and minimally 
invasive techniques should be explored. Progesterone antagonists and progesterone 
receptor modulators may have a major role in the future to treat conditions such as fibroids 
and endometriosis conservatively. Endometriosis accounts for approximately 20% of the 
hysterectomies currently performed. There is no doubt that these new approaches will help 
reduce the number of hysterectomies further. However, hysterectomy will always remain 
the first choice for infiltrative cancer of the uterus and for most forms of pelvic relaxation 
although vaginal pessaries are increasingly used in older women. Currently, utero-vaginal 
prolapse is the indication for 15% of hysterectomies. 
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